Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.14 USD | +0.78% | +2.39% | +0.98% |
09/04 | Immucell Corporation Reports Unaudited Sales Results for the Three Months and Twelve Months Ended March 31, 2024 | CI |
02/04 | ImmuCell Shares Fall After $20 Million Mixed Securities Shelf Filing | MT |
Sales 2022 | 18.57M 1.55B | Sales 2023 | 17.47M 1.46B | Capitalization | 39.45M 3.29B |
---|---|---|---|---|---|
Net income 2022 | -2M -167M | Net income 2023 | -5M -417M | EV / Sales 2022 | 2.91 x |
Net Debt 2022 | 6.69M 558M | Net Debt 2023 | 15.71M 1.31B | EV / Sales 2023 | 3.16 x |
P/E ratio 2022 |
-18.9
x | P/E ratio 2023 |
-6.79
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 71.37% |
Latest transcript on ImmuCell Corporation
1 day | +0.78% | ||
1 week | +2.39% | ||
Current month | -3.02% | ||
1 month | -2.84% | ||
3 months | -4.46% | ||
6 months | +7.99% | ||
Current year | +0.98% |
Managers | Title | Age | Since |
---|---|---|---|
Michael Brigham
CEO | Chief Executive Officer | 63 | 01/89/01 |
Bobbi Brockmann
BRD | Director/Board Member | 48 | 01/10/01 |
Corporate Officer/Principal | 68 | 05/16/05 |
Members of the board | Title | Age | Since |
---|---|---|---|
Michael Brigham
CEO | Chief Executive Officer | 63 | 01/89/01 |
David Tomsche
CHM | Chairman | 67 | 21/06/21 |
Bobbi Brockmann
BRD | Director/Board Member | 48 | 01/10/01 |
Date | Price | Change | Volume |
---|---|---|---|
26/24/26 | 5.14 | +0.78% | 1,776 |
25/24/25 | 5.1 | +1.19% | 6,409 |
24/24/24 | 5.04 | +0.20% | 7,163 |
22/24/22 | 5.03 | +0.20% | 3,262 |
19/24/19 | 5.02 | -0.59% | 3,187 |
Delayed Quote Nasdaq, April 27, 2024 at 02:00 am IST
More quotes1st Jan change | Capi. | |
---|---|---|
+0.98% | 40.22M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- ICCC Stock